A Randomized, Double-Blind, Placebo Controlled Trial Evaluating the Impact of Nystatin on the Development of Oral Irritation in Patients Receiving High Dose Intravenous Interleukin-2
In patients who are receiving intravenous high dose Interleukin-2, patients will be
randomized into two groups: group one will receive nystatin swish and swallow immediately
before initiation of IL-2, and the second group will receive a placebo. The patients in
each group will be monitored and evaluated for differences in the rate and severity of
development of oral irritation during treatment. They will also be studied for differences
between the two groups in the number of doses of IL-2 taken.
Interventional
Endpoint Classification: Efficacy Study, Primary Purpose: Treatment
United States: Federal Government
990097
NCT00001812
April 1999
August 2000
Name | Location |
---|---|
National Cancer Institute (NCI) | Bethesda, Maryland 20892 |